No Xeljanz Plan Yet From FDA

(MedPage Today) -- WASHINGTON--The FDA will await "further information" before making any moves to beef up label warnings or impose restrictions on tofacitinib (Xeljanz), the agency said Thursday.Last week, you may recall, drugmaker Pfizer...